Financials · CRVS

Corvus Pharmaceuticals Inc. (CRVS) financials

For the twelve months ended Sep 30, 2026, Corvus Pharmaceuticals Inc. reported -$64.31M of net income.

Net income, TTM
-$64.31M
Free cash flow, TTM
-$47.94M
EPS, diluted, TTM
-$0.74
Cash
$15.01M
Market cap
$897.5M
Annual net income-$15.28M
FY2016FY2025
Annual free cash flow-$32.97M
FY2016FY2025

CRVS revenue and earnings growth

CRVS net incomeQ3 2026-$20.34M

CRVS net income was -$20.34M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.16M a year earlier. For the full fiscal 2025 it was -$15.28M, compared with -$62.29M in fiscal 2024.

CRVS EPSQ3 2026-$0.22

CRVS diluted EPS was -$0.22 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.12 a year earlier. For the full fiscal 2025 it was -$0.53, compared with -$1.02 in fiscal 2024.

CRVS free cash flowQ3 2026-$12.28M

CRVS free cash flow was -$12.28M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$9.57M a year earlier. For the full fiscal 2025 it was -$32.97M.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Research and development$33.72M$19.39M$16.53M$24.47M$29.11M$31.83M$37.98M$38.59M$46.30M$29.36M
Selling, general and admin$9.25M$8.16M$6.88M$8.10M$9.52M$11.93M$10.88M$10.64M$10.22M$7.62M
Operating income-$42.97M-$27.55M-$23.41M-$32.56M-$38.63M-$43.76M-$48.85M-$49.22M-$56.52M-$36.98M
Pre-tax income-$13.32M-$59.10M-$21.75M-$31.30M-$43.24M-$6.00M-$46.67M-$46.94M-$55.66M-$36.38M
Income tax$0$0$0$0$0$0$0$0$0$0
Net income-$15.28M-$62.29M-$27.03M-$41.31M-$43.24M-$6.00M-$46.67M-$46.94M-$55.66M-$36.38M
EPS, basic-$0.19-$1.02-$0.56-$0.89-$1.03-$0.20-$1.59-$1.71-$2.72-$2.36
EPS, diluted-$0.53-$1.02-$0.56-$0.89-$1.03-$0.20-$1.59-$1.71-$2.72-$2.36
Diluted shares79.7M61.0M48.0M46.6M41.9M29.5M29.3M27.5M20.5M15.4M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$4.58M$8.74M$12.62M$13.16M$63.46M$16.45M$5.15M$39.20M$45.11M$5.05M
Receivables$37.0K$75.0K$26.0K$588.0K------
Current assets$58.21M$54.41M$27.96M$43.66M$71.31M$45.34M$79.34M$115.59M$91.23M$136.03M
Total assets$71.12M$68.91M$45.55M$68.24M$109.45M$85.53M$83.65M$118.23M$94.78M$140.15M
Current liabilities$9.38M$35.40M$6.87M$10.75M$9.69M$12.15M$10.22M$7.03M$8.97M$5.94M
Total liabilities$9.91M$36.34M$6.87M$12.13M$12.29M$13.38M$12.54M$7.90M$9.94M$7.35M
Shareholders' equity$61.20M$32.57M$38.68M$56.12M$97.16M$72.15M$71.11M$110.34M$84.83M$132.80M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$32.80M-$25.42M-$23.93M-$27.02M-$36.72M-$34.78M-$37.32M-$40.99M-$46.21M-$27.86M
Capital expenditures$174.0K-$34.0K$269.0K$5.0K$76.0K$25.0K$355.0K$266.0K$2.20M
Free cash flow-$32.97M--$23.97M-$27.29M-$36.72M-$34.85M-$37.35M-$41.34M-$46.48M-$30.06M
Investing cash flow-$7.80M-$27.48M$15.54M-$23.28M$21.56M$44.77M$3.25M-$30.19M$84.83M-$42.56M
Financing cash flow$36.43M$49.03M$7.86M$0$62.16M$1.31M$24.0K$65.27M$1.44M$71.36M
Stock-based compensation$5.33M$3.00M$2.15M$2.69M$4.23M$5.75M$7.35M$7.13M$6.23M$3.83M
Depreciation and amortization$105.0K$85.0K$151.0K$367.0K$460.0K$632.0K$743.0K$847.0K$842.0K$594.0K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Return on equity-25.0%-191.3%-69.9%-73.6%-44.5%-8.3%-65.6%-42.5%-65.6%-27.4%
Return on assets-21.5%-90.4%-59.3%-60.5%-39.5%-7.0%-55.8%-39.7%-58.7%-26.0%
Current ratio6.211.544.074.067.363.737.7616.4510.1722.89

Source: XBRL data Corvus Pharmaceuticals Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CRVS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CRVS---$64.31M-$897.5M
LLY$86.46B+45.5%$27.58B31.9%$1.36T
JNJ$99.33B+7.8%$16.09B16.2%$687.89B
ABBV$66.01B+10.7%$10.34B15.7%$521.50B
MRK$67.38B+4.9%$2.45B3.6%$364.26B
NVS$54.53B+8.4%$13.98B25.6%$306.26B
AZN$58.74B+8.6%$10.22B17.4%$286.03B
ABT$48.23B+10.0%$4.70B9.7%$187.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.33B

CRVS FAQ

6 questions
  • Is CRVS profitable?
    No. Corvus Pharmaceuticals Inc. reported a net loss of $64.31M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CRVS have?
    Corvus Pharmaceuticals Inc. reported $15.01M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • What is CRVS free cash flow?
    Corvus Pharmaceuticals Inc. generated -$47.94M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$47.18M less capital expenditures.
  • What is CRVS earnings per share?
    Diluted earnings per share were -$0.74 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CRVS last report financial results?
    The latest statements here come from Corvus Pharmaceuticals Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this CRVS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Corvus Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.